Which has higher valuation & earnings, TLX or AMPH?

Amphastar Pharmaceuticals has lower revenue, but higher earnings than Telix Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telix Pharmaceuticals $803.79M 3.89 -$7.12M N/A N/A Amphastar Pharmaceuticals $719.89M 1.19 $98.09M $1.66 11.68

Does the media favor TLX or AMPH?

In the previous week, Amphastar Pharmaceuticals had 5 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 7 mentions for Amphastar Pharmaceuticals and 2 mentions for Telix Pharmaceuticals. Telix Pharmaceuticals' average media sentiment score of 0.12 beat Amphastar Pharmaceuticals' score of -0.03 indicating that Telix Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telix Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Amphastar Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer AMPH or DYN?

In the previous week, Dyne Therapeutics had 2 more articles in the media than Amphastar Pharmaceuticals. MarketBeat recorded 9 mentions for Dyne Therapeutics and 7 mentions for Amphastar Pharmaceuticals. Dyne Therapeutics' average media sentiment score of 0.65 beat Amphastar Pharmaceuticals' score of -0.03 indicating that Dyne Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amphastar Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Dyne Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AMPH or RCUS?

In the previous week, Arcus Biosciences had 14 more articles in the media than Amphastar Pharmaceuticals. MarketBeat recorded 21 mentions for Arcus Biosciences and 7 mentions for Amphastar Pharmaceuticals. Arcus Biosciences' average media sentiment score of 0.89 beat Amphastar Pharmaceuticals' score of -0.03 indicating that Arcus Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amphastar Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Arcus Biosciences 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media favor AMPH or TNGX?

In the previous week, Tango Therapeutics had 9 more articles in the media than Amphastar Pharmaceuticals. MarketBeat recorded 16 mentions for Tango Therapeutics and 7 mentions for Amphastar Pharmaceuticals. Amphastar Pharmaceuticals' average media sentiment score of -0.03 beat Tango Therapeutics' score of -0.18 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amphastar Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Tango Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 5 Very Negative mention(s) Neutral

Which has better valuation and earnings, KLRA or AMPH?

Amphastar Pharmaceuticals has higher revenue and earnings than Kailera Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kailera Therapeutics N/A N/A N/A N/A N/A Amphastar Pharmaceuticals $719.89M 1.19 $98.09M $1.66 11.68

Does the media prefer KLRA or AMPH?

In the previous week, Amphastar Pharmaceuticals had 3 more articles in the media than Kailera Therapeutics. MarketBeat recorded 7 mentions for Amphastar Pharmaceuticals and 4 mentions for Kailera Therapeutics. Kailera Therapeutics' average media sentiment score of 0.49 beat Amphastar Pharmaceuticals' score of -0.03 indicating that Kailera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kailera Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Amphastar Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Amphastar Pharmaceuticals (AMPH) Competitors

$19.39 -0.35 (-1.77%)

Closing price 04:00 PM Eastern

Extended Trading

$19.40 +0.00 (+0.03%)

As of 04:10 PM Eastern

Compare

AMPH vs. TLX, DYN, RCUS, TNGX, and KLRA

Should you buy Amphastar Pharmaceuticals stock or one of its competitors? MarketBeat compares Amphastar Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Amphastar Pharmaceuticals include Telix Pharmaceuticals (TLX), Dyne Therapeutics (DYN), Arcus Biosciences (RCUS), Tango Therapeutics (TNGX), and Kailera Therapeutics (KLRA). These companies are all part of the "pharmaceutical products" industry.

How does Amphastar Pharmaceuticals compare to Telix Pharmaceuticals?

Telix Pharmaceuticals (NASDAQ:TLX) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, media sentiment, earnings, risk and dividends.

In the previous week, Amphastar Pharmaceuticals had 5 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 7 mentions for Amphastar Pharmaceuticals and 2 mentions for Telix Pharmaceuticals. Telix Pharmaceuticals' average media sentiment score of 0.12 beat Amphastar Pharmaceuticals' score of -0.03 indicating that Telix Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Telix Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Amphastar Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

65.1% of Amphastar Pharmaceuticals shares are held by institutional investors. 29.6% of Amphastar Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Amphastar Pharmaceuticals has a net margin of 11.00% compared to Telix Pharmaceuticals' net margin of 0.00%. Amphastar Pharmaceuticals' return on equity of 15.12% beat Telix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telix Pharmaceuticals	N/A	N/A	N/A
Amphastar Pharmaceuticals	11.00%	15.12%	7.14%

Telix Pharmaceuticals presently has a consensus target price of $21.13, suggesting a potential upside of 129.12%. Amphastar Pharmaceuticals has a consensus target price of $24.00, suggesting a potential upside of 23.78%. Given Telix Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Telix Pharmaceuticals is more favorable than Amphastar Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telix Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Amphastar Pharmaceuticals	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.88

Telix Pharmaceuticals has a beta of -0.1, indicating that its stock price is 110% less volatile than the broader market. Comparatively, Amphastar Pharmaceuticals has a beta of 0.91, indicating that its stock price is 9% less volatile than the broader market.

Amphastar Pharmaceuticals has lower revenue, but higher earnings than Telix Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telix Pharmaceuticals	$803.79M	3.89	-$7.12M	N/A	N/A
Amphastar Pharmaceuticals	$719.89M	1.19	$98.09M	$1.66	11.68

Summary

Amphastar Pharmaceuticals beats Telix Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Amphastar Pharmaceuticals compare to Dyne Therapeutics?

Amphastar Pharmaceuticals (NASDAQ:AMPH) and Dyne Therapeutics (NASDAQ:DYN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability.

Amphastar Pharmaceuticals has higher revenue and earnings than Dyne Therapeutics. Dyne Therapeutics is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amphastar Pharmaceuticals	$719.89M	1.19	$98.09M	$1.66	11.68
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.22	N/A

Amphastar Pharmaceuticals has a beta of 0.91, indicating that its stock price is 9% less volatile than the broader market. Comparatively, Dyne Therapeutics has a beta of 1.09, indicating that its stock price is 9% more volatile than the broader market.

In the previous week, Dyne Therapeutics had 2 more articles in the media than Amphastar Pharmaceuticals. MarketBeat recorded 9 mentions for Dyne Therapeutics and 7 mentions for Amphastar Pharmaceuticals. Dyne Therapeutics' average media sentiment score of 0.65 beat Amphastar Pharmaceuticals' score of -0.03 indicating that Dyne Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amphastar Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Dyne Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Amphastar Pharmaceuticals presently has a consensus price target of $24.00, indicating a potential upside of 23.78%. Dyne Therapeutics has a consensus price target of $35.00, indicating a potential upside of 108.21%. Given Dyne Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Dyne Therapeutics is more favorable than Amphastar Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amphastar Pharmaceuticals	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.88
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	3 Strong Buy rating(s)	2.94

Amphastar Pharmaceuticals has a net margin of 11.00% compared to Dyne Therapeutics' net margin of 0.00%. Amphastar Pharmaceuticals' return on equity of 15.12% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amphastar Pharmaceuticals	11.00%	15.12%	7.14%
Dyne Therapeutics	N/A	-58.28%	-46.77%

65.1% of Amphastar Pharmaceuticals shares are held by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are held by institutional investors. 29.6% of Amphastar Pharmaceuticals shares are held by insiders. Comparatively, 9.5% of Dyne Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Amphastar Pharmaceuticals and Dyne Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Amphastar Pharmaceuticals compare to Arcus Biosciences?

Amphastar Pharmaceuticals (NASDAQ:AMPH) and Arcus Biosciences (NYSE:RCUS) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.

In the previous week, Arcus Biosciences had 14 more articles in the media than Amphastar Pharmaceuticals. MarketBeat recorded 21 mentions for Arcus Biosciences and 7 mentions for Amphastar Pharmaceuticals. Arcus Biosciences' average media sentiment score of 0.89 beat Amphastar Pharmaceuticals' score of -0.03 indicating that Arcus Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amphastar Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arcus Biosciences	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are owned by institutional investors. 29.6% of Amphastar Pharmaceuticals shares are owned by insiders. Comparatively, 9.6% of Arcus Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Amphastar Pharmaceuticals presently has a consensus target price of $24.00, suggesting a potential upside of 23.78%. Arcus Biosciences has a consensus target price of $35.10, suggesting a potential upside of 50.94%. Given Arcus Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Arcus Biosciences is more favorable than Amphastar Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amphastar Pharmaceuticals	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.88
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58

Amphastar Pharmaceuticals has a net margin of 11.00% compared to Arcus Biosciences' net margin of -156.36%. Amphastar Pharmaceuticals' return on equity of 15.12% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amphastar Pharmaceuticals	11.00%	15.12%	7.14%
Arcus Biosciences	-156.36%	-68.97%	-35.27%

Amphastar Pharmaceuticals has higher revenue and earnings than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amphastar Pharmaceuticals	$719.89M	1.19	$98.09M	$1.66	11.68
Arcus Biosciences	$247M	11.84	-$353M	-$3.18	N/A

Amphastar Pharmaceuticals has a beta of 0.91, indicating that its stock price is 9% less volatile than the broader market. Comparatively, Arcus Biosciences has a beta of 0.85, indicating that its stock price is 15% less volatile than the broader market.

Summary

Amphastar Pharmaceuticals beats Arcus Biosciences on 9 of the 16 factors compared between the two stocks.

How does Amphastar Pharmaceuticals compare to Tango Therapeutics?

Amphastar Pharmaceuticals (NASDAQ:AMPH) and Tango Therapeutics (NASDAQ:TNGX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.

65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are owned by institutional investors. 29.6% of Amphastar Pharmaceuticals shares are owned by company insiders. Comparatively, 6.5% of Tango Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Amphastar Pharmaceuticals has a net margin of 11.00% compared to Tango Therapeutics' net margin of -151.15%. Amphastar Pharmaceuticals' return on equity of 15.12% beat Tango Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amphastar Pharmaceuticals	11.00%	15.12%	7.14%
Tango Therapeutics	-151.15%	-41.54%	-33.44%

Amphastar Pharmaceuticals has higher revenue and earnings than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amphastar Pharmaceuticals	$719.89M	1.19	$98.09M	$1.66	11.68
Tango Therapeutics	$62.38M	71.72	-$101.59M	-$0.83	N/A

Amphastar Pharmaceuticals presently has a consensus target price of $24.00, suggesting a potential upside of 23.78%. Tango Therapeutics has a consensus target price of $34.17, suggesting a potential upside of 10.46%. Given Amphastar Pharmaceuticals' higher probable upside, analysts plainly believe Amphastar Pharmaceuticals is more favorable than Tango Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amphastar Pharmaceuticals	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.88
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

Amphastar Pharmaceuticals has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market. Comparatively, Tango Therapeutics has a beta of 1.19, suggesting that its stock price is 19% more volatile than the broader market.

In the previous week, Tango Therapeutics had 9 more articles in the media than Amphastar Pharmaceuticals. MarketBeat recorded 16 mentions for Tango Therapeutics and 7 mentions for Amphastar Pharmaceuticals. Amphastar Pharmaceuticals' average media sentiment score of -0.03 beat Tango Therapeutics' score of -0.18 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amphastar Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tango Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	5 Very Negative mention(s)	Neutral

Summary

Amphastar Pharmaceuticals beats Tango Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Amphastar Pharmaceuticals compare to Kailera Therapeutics?

Kailera Therapeutics (NASDAQ:KLRA) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability.

In the previous week, Amphastar Pharmaceuticals had 3 more articles in the media than Kailera Therapeutics. MarketBeat recorded 7 mentions for Amphastar Pharmaceuticals and 4 mentions for Kailera Therapeutics. Kailera Therapeutics' average media sentiment score of 0.49 beat Amphastar Pharmaceuticals' score of -0.03 indicating that Kailera Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kailera Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Amphastar Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Kailera Therapeutics presently has a consensus price target of $42.75, indicating a potential upside of 117.01%. Amphastar Pharmaceuticals has a consensus price target of $24.00, indicating a potential upside of 23.78%. Given Kailera Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Kailera Therapeutics is more favorable than Amphastar Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kailera Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00
Amphastar Pharmaceuticals	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.88

65.1% of Amphastar Pharmaceuticals shares are held by institutional investors. 29.6% of Amphastar Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Amphastar Pharmaceuticals has a net margin of 11.00% compared to Kailera Therapeutics' net margin of 0.00%. Amphastar Pharmaceuticals' return on equity of 15.12% beat Kailera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kailera Therapeutics	N/A	N/A	N/A
Amphastar Pharmaceuticals	11.00%	15.12%	7.14%

Amphastar Pharmaceuticals has higher revenue and earnings than Kailera Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kailera Therapeutics	N/A	N/A	N/A	N/A	N/A
Amphastar Pharmaceuticals	$719.89M	1.19	$98.09M	$1.66	11.68

Summary

Amphastar Pharmaceuticals beats Kailera Therapeutics on 7 of the 12 factors compared between the two stocks.

Get Amphastar Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AMPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AMPH vs. The Competition

Export

Metric	Amphastar Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$870.39M	$5.87B	$6.49B	$11.99B
Dividend Yield	N/A	0.69%	2.67%	5.57%
P/E Ratio	11.68	8.50	20.24	21.95
Price / Sales	1.19	20.87	507.57	108.00
Price / Cash	4.64	8.41	26.99	37.25
Price / Book	1.13	4.12	10.28	6.78
Net Income	$98.09M	$99.67M	$3.57B	$337.51M
7 Day Performance	5.27%	-1.98%	-1.43%	-2.72%
1 Month Performance	2.05%	0.63%	3.27%	1.87%
1 Year Performance	-25.39%	129.11%	23.37%	26.61%

Amphastar Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AMPH Amphastar Pharmaceuticals	3.962 of 5 stars	$19.39 -1.8%	$24.00 +23.8%	-24.0%	$870.39M	$719.89M	11.68	1,976
TLX Telix Pharmaceuticals	4.5057 of 5 stars	$9.15 -2.9%	$21.13 +131.0%	-44.5%	$3.20B	$803.79M	N/A	1,184
DYN Dyne Therapeutics	3.1239 of 5 stars	$17.25 -7.4%	$35.00 +103.0%	+15.9%	$3.20B	N/A	N/A	100
RCUS Arcus Biosciences	3.1534 of 5 stars	$24.42 -5.1%	$33.89 +38.8%	+131.7%	$3.19B	$236M	N/A	500	News Coverage Analyst Revision
TNGX Tango Therapeutics	2.028 of 5 stars	$21.51 -6.9%	$32.27 +50.1%	+374.6%	$3.18B	$62.38M	N/A	90	Trending News Analyst Upgrade Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AMPH) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Amphastar Pharmaceuticals (AMPH) Competitors

AMPH vs. TLX, DYN, RCUS, TNGX, and KLRA

How does Amphastar Pharmaceuticals compare to Telix Pharmaceuticals?

Summary

How does Amphastar Pharmaceuticals compare to Dyne Therapeutics?

Summary

How does Amphastar Pharmaceuticals compare to Arcus Biosciences?

Summary

How does Amphastar Pharmaceuticals compare to Tango Therapeutics?

Summary

How does Amphastar Pharmaceuticals compare to Kailera Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMPH vs. The Competition

Amphastar Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Amphastar Pharmaceuticals (AMPH) Competitors

AMPH vs. TLX, DYN, RCUS, TNGX, and KLRA

How does Amphastar Pharmaceuticals compare to Telix Pharmaceuticals?

Does the media favor TLX or AMPH?

Do insiders & institutionals have more ownership in TLX or AMPH?

Is TLX or AMPH more profitable?

Do analysts prefer TLX or AMPH?

Which has more volatility & risk, TLX or AMPH?

Which has higher valuation & earnings, TLX or AMPH?

Summary

How does Amphastar Pharmaceuticals compare to Dyne Therapeutics?

Which has stronger earnings and valuation, AMPH or DYN?

Which has more volatility & risk, AMPH or DYN?

Does the media prefer AMPH or DYN?

Do analysts recommend AMPH or DYN?

Is AMPH or DYN more profitable?

Do institutionals & insiders believe in AMPH or DYN?

Summary

How does Amphastar Pharmaceuticals compare to Arcus Biosciences?

Does the media prefer AMPH or RCUS?

Do insiders & institutionals hold more shares of AMPH or RCUS?

Do analysts prefer AMPH or RCUS?

Is AMPH or RCUS more profitable?

Which has stronger valuation & earnings, AMPH or RCUS?

Which has more risk and volatility, AMPH or RCUS?

Summary

How does Amphastar Pharmaceuticals compare to Tango Therapeutics?

Do institutionals & insiders hold more shares of AMPH or TNGX?

Is AMPH or TNGX more profitable?

Which has preferable valuation and earnings, AMPH or TNGX?

Do analysts prefer AMPH or TNGX?

Which has more volatility & risk, AMPH or TNGX?

Does the media favor AMPH or TNGX?

Summary

How does Amphastar Pharmaceuticals compare to Kailera Therapeutics?

Does the media prefer KLRA or AMPH?

Do analysts recommend KLRA or AMPH?

Do insiders & institutionals hold more shares of KLRA or AMPH?

Is KLRA or AMPH more profitable?

Which has better valuation and earnings, KLRA or AMPH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMPH vs. The Competition

Amphastar Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools